Skip to main content

Table 2 Pain assessment

From: Hormone replacement therapy in morphine-induced hypogonadic male chronic pain patients

Parameter

Months

 

T0

T3

T6

T12

VAS (0-100)

67.14 ± 10.9

75.57 ± 6.44

66.42 ± 9.36

64.28 ± 9.15

VAS last week (0-100)

62.00 ± 11.15

82.85 ± 5.10

77.14 ± 6.80

72.14 ± 5.96

Area %

30.78 ± 10.03

29.04 ± 8.17

30.28 ± 7.77

31.00 ± 7.12

QUID Sensory

20.85 ± 1.86

14.57 ± 2.33*

12.85 ± 2.47#

16.00 ± 2.96

QUID Affective

11.14 ± 1.69

8.71 ± 1.71

7.57 ± 2.63

7.14 ± 2.07#

QUID Evaluative

17.28 ± 1.78

10.71 ± 2.75*

10.85 ± 2.82§

10.28 ± 2.92#

QUID Miscellaneous

11.71 ± 0.64

7.42 ± 1.81

6.14 ± 1.79§

7.00 ± 2.03

QUID Total

61.00 ± 5.06

41.42 ± 7.62*

37.42 ± 9.05*

40.42 ± 8.83*

  1. VAS, Area% and QUID, values recorded before (T0) and after 3 (T3), 6 (T6) and 12 (T12) months of testosterone replacement therapy. Values are mean ± SEM (n = 9). Wilcoxon test: * p < 0.01 vs T0; # p < 0.02 vs T0; § p < 0.04 vs T0
Back to article page

Reproductive Biology and Endocrinology

ISSN: 1477-7827

Contact us